10-Q: BioVie Inc. Reports Q3 2024 Financial Results, Provides Update on Clinical Programs

BioVie Inc. released its unaudited financial results for the third quarter of 2024, detailing progress in its clinical programs and financial position.

Summary

• BioVie Inc. reported a net loss of $8.1 million for the three months ended March 31, 2024, compared to a net loss of $15.0 million for the same period in 2023.
• The company's operating expenses decreased to $7.7 million from $13.8 million year-over-year, primarily due to reduced research and development costs.
• Research and development expenses were $5.7 million for the quarter, down from $11.2 million in the prior year, reflecting the completion of certain clinical trials.
• Selling, general, and administrative expenses also decreased to $2.0 million from $2.5 million year-over-year.
• For the nine months ended March 31, 2024, the net loss was $27.2 million, compared to $41.1 million for the same period in 2023.
• The company's cash and cash equivalents stood at $30.4 million as of March 31, 2024, with working capital of approximately $18.1 million.
• BioVie completed a public offering in March 2024, raising gross proceeds of $21.0 million.
• The company is developing drug therapies for neurological and neurodegenerative disorders and liver disease, including bezisterim (NE3107) and BIV201.
• A Phase 3 trial of bezisterim (NE3107) for Alzheimer's disease was impacted by protocol deviations at several study sites, leading to patient exclusions and underpowering the study.
• A Phase 2 study of bezisterim (NE3107) for Parkinson's disease was completed in December 2022, meeting its primary and secondary objectives.
• BioVie received a $13.1 million grant from the U.S. Department of Defense for a Phase 2b trial of bezisterim (NE3107) for long COVID, expected to commence in early 2025.
• The company is finalizing protocol designs for a Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as reduced losses, a significant grant, and a successful capital raise, the issues with the Alzheimer's trial, the delay in the Parkinson's trial, and the going concern uncertainty raise significant concerns.

Positives

• The company significantly reduced its net loss and operating expenses compared to the same period last year.
• BioVie secured a substantial grant for its long COVID program, providing non-dilutive funding.
• The company successfully completed a public offering, strengthening its financial position.
• There is a potential efficacy signal observed in the Alzheimer's trial, despite the issues with study sites.
• The Phase 2 Parkinson's disease study met its objectives, indicating the drug's safety and potential efficacy.

Negatives

• The Phase 3 Alzheimer's trial was significantly impacted by protocol deviations and potential scientific misconduct at multiple study sites.
• The exclusion of patients from the Alzheimer's trial resulted in the study being underpowered for its primary endpoints.
• The company's future operations are dependent on securing additional financing, raising concerns about its ability to continue as a going concern.
• The initiation of a Phase 3 study for Parkinson's disease is on hold pending additional funding.

Risks

• The company's reliance on third parties for clinical trials poses risks, as evidenced by the issues in the Alzheimer's trial.
• The company's financial statements have been prepared assuming it will continue as a going concern, which is uncertain.
• The company is subject to a shareholder class action lawsuit, which could result in significant costs and liabilities.
• The company may experience future dilution from equity offerings or the issuance of shares under various agreements.
• The company's majority shareholder has significant control, which could impact corporate decisions.
• The company has not generated any revenue and no revenues are expected in the foreseeable future.

Future Outlook

The company is exploring options for its Alzheimer's trial, including discussions with the FDA and designing a new Phase 3 study. The Phase 3 study for Parkinson's disease is on hold pending additional funding. The company anticipates the long COVID trial to commence by early 2025. The company is finalizing protocol designs for the Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis.

Management Comments

• Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.
• Management continues to pursue the Companys strategic plans.
• Management believes the shareholder lawsuit is without merit and intends to defend the case vigorously.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industry, focusing on developing treatments for neurodegenerative diseases and liver conditions. The company's focus on inflammation and insulin resistance as drivers of Alzheimer's and Parkinson's aligns with emerging scientific consensus. The company's long COVID program addresses a significant unmet medical need.

Comparison to Industry Standards

• The company's research and development spending is typical for a clinical-stage biotech company, with fluctuations based on the stage of clinical trials.
• The company's cash burn rate is high, as is typical for companies in this sector, and is dependent on raising additional capital.
• The company's reliance on third-party CROs is standard practice in the industry, but the issues with the Alzheimer's trial highlight the risks involved.
• The company's focus on novel mechanisms of action for its drug candidates is a common strategy in the biotech industry to differentiate from competitors.
• The company's pursuit of orphan drug status for BIV201 is a common strategy to gain market exclusivity and regulatory advantages.

Legal Proceedings

• A shareholder class action lawsuit has been filed against the company, alleging material misrepresentations and/or omissions of material fact relating to the company's business, operations, compliance, and prospects.

Related Party Transactions

• On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (Acuitas), the Company’s majority stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of 3,636,364 shares of the Company’s Common Stock, at a price of $1.65 per share (the PIPE Shares), and (ii) a warrant to purchase 7,272,728 shares of Common Stock (PIPE Warrant Shares), at an exercise price of $1.82, with a term of exercise of five years.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, clinical trial results, and the ongoing litigation.
• Employees are impacted by the company's financial stability and the progress of its clinical programs.
• Patients are impacted by the potential for new treatments for Alzheimer's, Parkinson's, long COVID, and liver disease.
• Creditors are impacted by the company's ability to repay its debts.
• Suppliers are impacted by the company's ability to continue its operations.

Next Steps

• The company will explore options for its Alzheimer's trial, including discussions with the FDA and designing a new Phase 3 study.
• The company will finalize protocol designs for a Phase 3 study of BIV201 for the treatment of ascites.
• The company anticipates the long COVID trial to commence by early 2025.
• The company will continue to seek additional funding for its clinical programs.

Key Dates

Keywords

BioVie, bezisterim, NE3107, BIV201, Alzheimer's disease, Parkinson's disease, long COVID, ascites, clinical trials, pharmaceutical, biotechnology, financial results, research and development